Monte Historical Income Statement

GLUE Stock  USD 8.35  0.01  0.12%   
Historical analysis of Monte Rosa income statement accounts such as Interest Expense of 4.5 M or Selling General Administrative of 17.5 M can show how well Monte Rosa Therapeutics performed in making a profits. Evaluating Monte Rosa income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Monte Rosa's future profits or losses.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Monte Rosa Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Monte Rosa Therapeutics is a good buy for the upcoming year.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

About Monte Income Statement Analysis

Monte Rosa Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Monte Rosa shareholders. The income statement also shows Monte investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Monte Rosa Income Statement Chart

At present, Monte Rosa's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Reconciled Depreciation is expected to grow to about 5.7 M, whereas Selling General Administrative is forecasted to decline to about 17.5 M.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Monte Rosa Therapeutics minus its cost of goods sold. It is profit before Monte Rosa operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Monte Rosa Therapeutics. It is also known as Monte Rosa overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Cost Of Revenue

Cost of Revenue is found on Monte Rosa Therapeutics income statement and represents the costs associated with goods and services Monte Rosa provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.
Most accounts from Monte Rosa's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Monte Rosa Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
At present, Monte Rosa's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Reconciled Depreciation is expected to grow to about 5.7 M, whereas Selling General Administrative is forecasted to decline to about 17.5 M.
 2021 2022 2023 2024 (projected)
Interest Expense1.1M3.8M4.3M4.5M
Depreciation And Amortization2.1M8.6M6.2M3.9M

Monte Rosa income statement Correlations

0.750.950.81-0.830.82-0.92-0.9-0.920.82-0.920.750.820.95-0.90.84-0.91-0.091.00.94-0.91
0.750.910.95-0.980.93-0.89-0.89-0.880.92-0.871.00.930.86-0.890.64-0.88-0.680.750.92-0.45
0.950.910.93-0.960.92-0.98-0.97-0.980.92-0.980.910.920.99-0.970.8-0.97-0.40.950.98-0.78
0.810.950.93-0.951.0-0.96-0.96-0.961.0-0.950.961.00.92-0.960.65-0.96-0.570.810.9-0.55
-0.83-0.98-0.96-0.95-0.930.940.940.94-0.930.93-0.98-0.93-0.920.94-0.690.930.62-0.83-0.960.59
0.820.930.921.0-0.93-0.96-0.97-0.961.0-0.960.941.00.93-0.960.63-0.96-0.530.820.89-0.57
-0.92-0.89-0.98-0.960.94-0.961.01.0-0.961.0-0.9-0.96-0.991.0-0.721.00.44-0.91-0.940.75
-0.9-0.89-0.97-0.960.94-0.971.01.0-0.971.0-0.9-0.97-0.991.0-0.671.00.46-0.9-0.920.73
-0.92-0.88-0.98-0.960.94-0.961.01.0-0.961.0-0.89-0.96-0.991.0-0.721.00.42-0.92-0.930.76
0.820.920.921.0-0.931.0-0.96-0.97-0.96-0.960.931.00.93-0.970.63-0.96-0.520.820.88-0.57
-0.92-0.87-0.98-0.950.93-0.961.01.01.0-0.96-0.88-0.96-0.991.0-0.711.00.41-0.92-0.930.76
0.751.00.910.96-0.980.94-0.9-0.9-0.890.93-0.880.940.86-0.90.63-0.89-0.690.750.92-0.46
0.820.930.921.0-0.931.0-0.96-0.97-0.961.0-0.960.940.93-0.960.63-0.96-0.530.820.89-0.57
0.950.860.990.92-0.920.93-0.99-0.99-0.990.93-0.990.860.93-0.990.77-0.99-0.350.950.95-0.82
-0.9-0.89-0.97-0.960.94-0.961.01.01.0-0.971.0-0.9-0.96-0.99-0.681.00.45-0.9-0.920.73
0.840.640.80.65-0.690.63-0.72-0.67-0.720.63-0.710.630.630.77-0.68-0.68-0.090.840.8-0.75
-0.91-0.88-0.97-0.960.93-0.961.01.01.0-0.961.0-0.89-0.96-0.991.0-0.680.43-0.91-0.930.75
-0.09-0.68-0.4-0.570.62-0.530.440.460.42-0.520.41-0.69-0.53-0.350.45-0.090.43-0.09-0.39-0.16
1.00.750.950.81-0.830.82-0.91-0.9-0.920.82-0.920.750.820.95-0.90.84-0.91-0.090.94-0.91
0.940.920.980.9-0.960.89-0.94-0.92-0.930.88-0.930.920.890.95-0.920.8-0.93-0.390.94-0.74
-0.91-0.45-0.78-0.550.59-0.570.750.730.76-0.570.76-0.46-0.57-0.820.73-0.750.75-0.16-0.91-0.74
Click cells to compare fundamentals

Monte Rosa Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.78)
Revenue Per Share
0.221
Return On Assets
(0.28)
Return On Equity
(0.61)
The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.